cygnus
GLP-1 Apprentice

If you'd like to save a click, this is their injectable GLP-1 drug. It looks like results were 12.3% loss through 28 weeks, which admittedly is not terribly exciting. Competition breeds innovation though, so keep 'em coming.
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
Pfizer Inc. (NYSE
FE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a...
finance.yahoo.com
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
Pfizer Inc. (NYSE
finance.yahoo.com
